<DOC>
	<DOCNO>NCT01986569</DOCNO>
	<brief_summary>The standard diagnostic workup recurrent metastatic breast cancer include biopsy determination tumor estrogen status accord National Comprehensive Cancer Network European Society Medical Oncology . Immunohistochemistry ( IHC ) currently commonly use method determine ER status . A investigational imaging tracer name 16-alpha- [ 18F ] -fluoro-17-beta-estradiol , [ 18F ] fluoroestradiol ( [ 18F ] FES ) act similarly vivo estradiol bind estrogen receptor ( ERs ) . Previous study human show efficacy [ 18F ] FES PET detect ER positive breast cancer without observed toxicity . The investigator hypothesize [ 18F ] FES PET image noninvasively assess ER status recurrent metastatic breast cancer lesion . In study , positive negative percent agreement IHC [ 18F ] FES determine .</brief_summary>
	<brief_title>Diagnostic Accuracy Safety Study FES PET/CT Assessment ER Status Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>A patient enrol patient meet follow inclusion criterion 1 . Patient ≥19 year age male female race/ethnicity 2 . Patients first recurrence stage IV disease American Joint Committee Cancer tumornodemetastasis stag system breast cancer 3 . Patients histologically confirm invasive primary breast carcinoma document result histology available . 4 . Patients scheduled undergo core needle biopsy surgery histological confirmation determination ER status recurrent distant metastatic cancer within 15 day [ 18F ] FES PET ; patient already underwent core needle biopsy recurrent distant metastatic cancer within 30 day [ 18F ] FES PET biopsy specimens available determination ER status . 5 . Discontinuation selective ER block agent include tamoxifen fulvestrant least 60 day prior [ 18F ] FES PET 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 A patient exclude study patient full fulfill inclusion criterion , follow condition observe 1 . Patient patient 's legally acceptable representative provide write informed consent 2 . The recurrent metastatic lesion schedule undergo biopsy locate breast , liver , ovary , uterus , bone 3 . Female patient pregnant nursing . Exclusion possibility pregnancy make one following : 1 ) woman physiologically post menopausal ( cessation menses 2 year ) , 2 ) woman surgically sterile ( documented bilateral oophorectomy and/or document hysterectomy , 3 ) woman childbearing potential , urine pregnancy test perform within 24 hour immediately prior administration [ 18F ] FES negative woman advise apply contraceptive measure participation study 4 . Adjuvant chemotherapy within 3 week prior [ 18F ] FES PET . 5 . Radiation therapy immuno/biologic therapy schedule give patient histologic confirmation biopsy [ 18F ] FES PET . 6 . Concurrent severe and/or uncontrolled and/or unstable medical disease cancer ( e.g . congestive heart failure , acute myocardial infarction , severe pulmonary disease , chronic renal hepatic disease could compromise participation study ) judgment investigator . 7 . Patient relative investigator , student investigator otherwise dependent 8 . Patient condition personal circumstance , judgment investigator , might interfere collection complete data 9 . Patient involved investigative , radioactive research procedure within 7 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Fluoroestradiol ( FES )</keyword>
	<keyword>PET/CT scan</keyword>
	<keyword>Estrogen Receptor</keyword>
	<keyword>Recurrent breast cancer</keyword>
	<keyword>Stage IV breast cancer</keyword>
</DOC>